A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Study to Evaluate the Efficacy and Safety of TF0023 Spray Versus Placebo in Functional Improvement of Patients With Ischemic Strokes
Phase of Trial: Phase II
Latest Information Update: 17 Mar 2017
At a glance
- Drugs TF 0023 (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Sponsors Techfields Pharma
- 07 Jun 2017 Biomarkers information updated
- 22 Sep 2016 Status changed from not yet recruiting to recruiting.
- 14 Sep 2016 Planned initiation date changed from 1 Jul 2016 to 1 Oct 2016.